Articles related to ANTITHROMBOTIC THERAPY

In patients with both cirrhosis and atrial fibrillation, apixaban initiation was associated with lower rates of major bleeding compared to rivaroxaban or warfarin, without compromising thromboembolic protection.

This article discusses the largest malpractice verdict awarded to an individual over 70 in Illinois, emphasizing the importance of rigorous INR monitoring in anticoagulated patients to avoid severe complications.

Managing venous thromboembolism effectively demands a nuanced understanding of updated clinical guidelines, which now differentiate treatment protocols based on specific risk assessments and patient comorbidities.

Researchers have uncovered a promising link between sulforaphane, a natural chemical in cruciferous vegetables, and improved outcomes in stroke treatment. This compound offers a novel approach to enhancing the effectiveness of existing therapies without the associated risk of bleeding.

For patients with cirrhosis facing venous thromboembolic events, the choice of anticoagulant—be it DOACs or LMWH—demands careful consideration of their unique hemostatic profile, emphasizing the need for personalized treatment strategies.

Venous thromboembolism presents a significant challenge in cancer care, with emerging evidence supporting the use of direct oral anticoagulants for improved outcomes. This highlights the evolving landscape of VTE management in oncology, stressing the importance of personalized treatment strategies.